XML 54 R37.htm IDEA: XBRL DOCUMENT
v3.22.1

Organization and Description of Business (Details) - shares | Feb. 08, 2019 | Feb. 08, 2016 | Aug. 31, 2017
--- | --- | --- | ---
Organization and Description of Business (Details) [Line Items] |  |  |
Percentage of common shares issued and outstanding |  |  | 73.00%
Common stock issued post-stock split |  | at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921 (52,936,583 pre-stock split) common shares of the Company and BriVision had become a wholly owned subsidiary of the Company. |
Common Stock [Member] |  |  |
Organization and Description of Business (Details) [Line Items] |  |  |
Common stock issued post-stock split |  | 1. ORGANIZATION AND DESCRIPTION OF BUSINESS ABVC BioPharma, Inc. (the “Company”), formerly known as American BriVision (Holding) Corporation, a Nevada corporation, through the Company’s operating entity, American BriVision Corporation (“BriVision”), which was incorporated in July 2015 in the State of Delaware, engages in biotechnology to fulfill unmet medical needs and focuses on the development of new drugs and medical devices derived from plants. BriVision develops its pipeline by carefully tracking new medical discoveries or medical device technologies in research institutions in the Asia-Pacific region. Pre-clinical, disease animal model and Phase I safety studies are examined closely by the Company to identify drugs that BriVision believes demonstrate efficacy and safety. Once a drug appears to be a good candidate for development and ultimately commercialization, BriVision licenses the drug or medical device from the original researchers and begins to introduce the drugs clinical plan to highly respected principal investigators in the United States, Australia and Taiwan to conduct a Phase II clinical trial. At present, clinical trials for the Company’s drugs and medical devices are being conducted at such world-famous institutions as Memorial Sloan Kettering Cancer Center (“MSKCC”) and MD Anderson Cancer Center. BriVision had no predecessor operations prior to its formation on July 21, 2015. Name Change The Company’s shareholders approved an amendment to the Company’s Articles of Incorporation to change the Company’s corporate name from American BriVision (Holding) Corporation to ABVC BioPharma, Inc. and approved and adopted the Certificate of Amendment to affect same at the 2020 annual meeting of shareholders (the “Annual Meeting”). The name change amendment to the Company’s Articles of Incorporation was filed with Nevada’s Secretary of State and became effective on March 8, 2021 and FINRA processed our request to change our name on April 30, 2021, which became effective as of May 3, 2021. The Company’s stock symbol remains ABVC. Reverse Merger On February 8, 2016, a Share Exchange Agreement (the “Share Exchange Agreement”) was entered into by and among the Company, BriVision, and Euro-Asia Investment & Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of the People’s Republic of China (“Euro-Asia”), being the owners of record of 164,387,376 (52,336,000 pre-stock split) shares of Common Stock of the Company, and the owners of record of all of the issued share capital of BriVision (the “BriVision Stock”). Pursuant to the Share Exchange Agreement, upon surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered in the name of each BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision as the new holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision Stock in the name of the Company, the Company issued 166,273,921 (52,936,583 pre-stock split) shares (the “Acquisition Stock”) (subject to adjustment for fractionalized shares as set forth below) of the Company’s Common Stock to the BriVision Shareholders (or their designees), and 163,159,952 (51,945,225 pre-stock split) shares of the Company’s Common Stock owned by Euro-Asia were cancelled and retired to treasury. The Acquisition Stock collectively represented 79.70% of the issued and outstanding Common Stock of the Company immediately after the Closing, in exchange for the BriVision Stock, representing 100% of the issued share capital of BriVision in a reverse merger (the “Merger”). Pursuant to the Merger, all of the issued and outstanding common shares of BriVision were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921 (52,936,583 pre-stock split) common shares of the Company and BriVision had become a wholly owned subsidiary of the Company. |
Share Exchange Agreement [Member] |  |  |
Organization and Description of Business (Details) [Line Items] |  |  |
Common stock issued post-stock split |  | 164,387,376 |
Common stock issued pre-stock split |  | 52,336,000 |
Share Exchange Agreement One [Member] |  |  |
Organization and Description of Business (Details) [Line Items] |  |  |
Common stock issued post-stock split |  | 166,273,921 |
Common stock issued pre-stock split |  | 52,936,583 |
Share Exchange Agreement Two [Member] |  |  |
Organization and Description of Business (Details) [Line Items] |  |  |
Common stock issued post-stock split |  | 163,159,952 |
Common stock issued pre-stock split |  | 51,945,225 |
Percentage of common shares issued and outstanding |  | 79.70% |
Percentage of issued share capital |  | 100.00% |
Share Exchange Agreement Four [Member] |  |  |
Organization and Description of Business (Details) [Line Items] |  |  |
Common stock issued post-stock split |  | 205,519,223 |
Common stock issued pre-stock split |  | 65,431,144 |
Merger Agreement [Member] |  |  |
Organization and Description of Business (Details) [Line Items] |  |  |
Common stock issued pre-stock split | 104,558,777 |  |
Share Exchange Agreement Three [Member] |  |  |
Organization and Description of Business (Details) [Line Items] |  |  |
Common stock issued post-stock split |  | 166,273,921 |
Common stock issued pre-stock split |  | 52,936,583 |

X
- Definition Common stock issued after stock split. + References No definition available. + Details
Name: | abvc_CommonStockIssuedAfterStockSplit
Namespace Prefix: | abvc_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Common stock issued before stock split. + References No definition available. + Details
Name: | abvc_CommonStockIssuedBeforeStockSplit
Namespace Prefix: | abvc_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | abvc_OrganizationandDescriptionofBusinessDetailsLineItems
Namespace Prefix: | abvc_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of common shares issued and outstanding. + References No definition available. + Details
Name: | abvc_PercentageOfCommonSharesIssuedAndOutstanding
Namespace Prefix: | abvc_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of issued share capital. + References No definition available. + Details
Name: | abvc_PercentageOfIssuedShareCapital
Namespace Prefix: | abvc_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770 + Details
Name: | us-gaap_StockholdersEquityNoteStockSplit
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=abvc_ShareExchangeAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=abvc_ShareExchangeAgreementOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=abvc_ShareExchangeAgreementTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=abvc_ShareExchangeAgreementFourMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=abvc_MergerAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=abvc_ShareExchangeAgreementThreeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |